American Association for Cancer Research
Browse
00085472can153352-sup-159331_1_supp_0_b3d7ly.pdf (689.8 kB)

Supplemental Figures from TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors

Download (689.8 kB)
journal contribution
posted on 2023-03-31, 00:25 authored by Laurie Menger, Anna Sledzinska, Katharina Bergerhoff, Frederick Arce Vargas, Julianne Smith, Laurent Poirot, Martin Pule, Javier Herrero, Karl S. Peggs, Sergio A. Quezada

PD-1-TALEN activity screen in murine thymoma EL4 cells.PD-1 gene inactivation in pmel-1 CD8+T cells and functional analysis. PD-1-TALEN activity in TRL from MCA205. Effector/memory phenotype of TRL from MCA205.

Funding

http://dx.doi.org/10.13039/501100000289

CRUK, Leukemia and Lymphoma Research

Department of Health and CRUK

History

ARTICLE ABSTRACT

Despite the promising efficacy of adoptive cell therapies (ACT) in melanoma, complete response rates remain relatively low and outcomes in other cancers are less impressive. The immunosuppressive nature of the tumor microenvironment and the expression of immune-inhibitory ligands, such as PD-L1/CD274 by the tumor and stroma are considered key factors limiting efficacy. The addition of checkpoint inhibitors (CPI) to ACT protocols bypasses some mechanisms of immunosuppression, but associated toxicities remain a significant concern. To overcome PD-L1–mediated immunosuppression and reduce CPI-associated toxicities, we used TALEN technology to render tumor-reactive T cells resistant to PD-1 signaling. Here, we demonstrate that inactivation of the PD-1 gene in melanoma-reactive CD8+ T cells and in fibrosarcoma-reactive polyclonal T cells enhanced the persistence of PD-1 gene-modified T cells at the tumor site and increased tumor control. These results illustrate the feasibility and potency of approaches incorporating advanced gene-editing technologies into ACT protocols to silence immune checkpoints as a strategy to overcome locally active immune escape pathways. Cancer Res; 76(8); 2087–93. ©2016 AACR.

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC